PEG-PLGA from PolySciTech used in development of Parkinson’s disease therapy

 

Parkinson’s disease affects the nervous system and leads to decreased motor control. A treatment for this disease is Levodopa however this drug has cardiovascular side effects which makes targeted delivery preferable to system. Recently, researchers at Sun Yat-sen University (China), Ocean University of China, and Johns Hopkins University, Used mPEG-PLGA (AK101) from PolySciTech (www.polyscitech.com) to investigate nanoparticle formulations for treatment of Parkinson’s disease by delivery of levodopa. This research holds promise to improve therapies against Parkinson’s disease. Read more: Nie, Tianqi, Zhiyu He, Jinchang Zhu, Kuntao Chen, Gregory P. Howard, Jesus Pacheco-Torres, Il Minn et al. "Non-invasive delivery of levodopa-loaded nanoparticles to the brain via lymphatic vasculature to enhance treatment of Parkinson’s disease." Nano Research: 1-13. https://link.springer.com/article/10.1007/s12274-020-3280-0

“Abstract: Levodopa (L-DOPA), a precursor of dopamine, is commonly prescribed for the treatment of the Parkinson’s disease (PD). However, oral administration of levodopa results in a high level of homocysteine in the peripheral circulation, thereby elevating the risk of cardiovascular disease, and limiting its clinical application. Here, we report a non-invasive method to deliver levodopa to the brain by delivering L-DOPA-loaded sub-50 nm nanoparticles via brain-lymphatic vasculature. The hydrophilic L-DOPA was successfully encapsulated into nanoparticles of tannic acid (TA)/polyvinyl alcohol (PVA) via hydrogen bonding using the flash nanocomplexation (FNC) process, resulting in a high L-DOPA-loading capacity and uniform size in a scalable manner. Pharmacodynamics analysis in a PD rat model demonstrated that the levels of dopamine and tyrosine hydroxylase, which indicate the dopaminergic neuron functions, were increased by 2- and 4-fold, respectively. Movement disorders and cerebral oxidative stress of the rats were significantly improved. This formulation exhibited a high degree of biocompatibility as evidenced by lack of induced inflammation or other pathological changes in major organs. This antioxidative and drug-delivery platform administered through the brain-lymphatic vasculature shows promise for clinical treatment of the PD.”